Table 1 gives a summary of the clinical phase III studies with at least 52 weeks duration on the efficacy of DPP-4 inhibitors compared to sulfonylureas as add on therapy to metformin, respectively, in patients not reaching their glycaemic goals with a monotherapy of metformin

Use of semaglutide for the preparation of a medicament for the treatment or delay of ovarian aging The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway
Combining semaglutide with other weight loss medications should only be considered under the guidance of a healthcare professional
Sexual side effects: Melanotan can cause unwanted erections (yep, really) and even priapism (a painful, prolonged erection)
Reference: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes by A